Cargando…

Mutagenesis testing program.

Until recently, mutagenicity testing was done on preselected compounds in a manner in which the testing laboratories knew the identity of the substances under test and the "expected" results, i.e., positive for compounds selected because of their carcinogenicity and negative for food addit...

Descripción completa

Detalles Bibliográficos
Autor principal: Valcovic, L R
Formato: Texto
Lenguaje:English
Publicado: 1977
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1637324/
https://www.ncbi.nlm.nih.gov/pubmed/598350
_version_ 1782130834677956608
author Valcovic, L R
author_facet Valcovic, L R
author_sort Valcovic, L R
collection PubMed
description Until recently, mutagenicity testing was done on preselected compounds in a manner in which the testing laboratories knew the identity of the substances under test and the "expected" results, i.e., positive for compounds selected because of their carcinogenicity and negative for food additives. There is no completed study in which substances were tested blind using a standardized protocol. Also, little attention has been placed on reproducibility and variability within and between laboratories. These aspects are currently under investigation in microbial systems by NCI but the results will not be available 1-2 years. In the NIEHS testing program a large number of substances will be tested in a blind study. At present we suggest use of a short-term testing system consisting of microbial tests plus mammalian activation systems (Tier 1), two different Drosophila systems (Tier 2) and four different whole animal systems (Tier 3). The compounds will initially be screened for mutagenicity in Tier 1, and the results obtained in Tier 1 together with what is known about the compound otherwise will dictate the decision whether to continue the test of the compound in Tier 2 and Tier 3.
format Text
id pubmed-1637324
institution National Center for Biotechnology Information
language English
publishDate 1977
record_format MEDLINE/PubMed
spelling pubmed-16373242006-11-17 Mutagenesis testing program. Valcovic, L R Environ Health Perspect Research Article Until recently, mutagenicity testing was done on preselected compounds in a manner in which the testing laboratories knew the identity of the substances under test and the "expected" results, i.e., positive for compounds selected because of their carcinogenicity and negative for food additives. There is no completed study in which substances were tested blind using a standardized protocol. Also, little attention has been placed on reproducibility and variability within and between laboratories. These aspects are currently under investigation in microbial systems by NCI but the results will not be available 1-2 years. In the NIEHS testing program a large number of substances will be tested in a blind study. At present we suggest use of a short-term testing system consisting of microbial tests plus mammalian activation systems (Tier 1), two different Drosophila systems (Tier 2) and four different whole animal systems (Tier 3). The compounds will initially be screened for mutagenicity in Tier 1, and the results obtained in Tier 1 together with what is known about the compound otherwise will dictate the decision whether to continue the test of the compound in Tier 2 and Tier 3. 1977-10 /pmc/articles/PMC1637324/ /pubmed/598350 Text en
spellingShingle Research Article
Valcovic, L R
Mutagenesis testing program.
title Mutagenesis testing program.
title_full Mutagenesis testing program.
title_fullStr Mutagenesis testing program.
title_full_unstemmed Mutagenesis testing program.
title_short Mutagenesis testing program.
title_sort mutagenesis testing program.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1637324/
https://www.ncbi.nlm.nih.gov/pubmed/598350
work_keys_str_mv AT valcoviclr mutagenesistestingprogram